Two Tower Place
7th Floor
South San Francisco, CA 94080
United States
833 509 4583
https://www.assemblybio.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 65
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Jason A. Okazaki | CEO, President & Director | 1.07M | N/A | 1976 |
Dr. William E. Delaney IV, Ph.D. | Chief Scientific Officer | 723.24k | N/A | 1972 |
Dr. Nicole S. White Ph.D. | Chief Manufacturing Officer | 616.94k | N/A | N/A |
Dr. Uri A. Lopatin M.D. | Co-Founder and Clinical & Scientific Advisor | 608.55k | N/A | 1972 |
Dr. Adam Zlotnick | Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board | N/A | N/A | N/A |
Jeanette M Bjorkquist | Executive Director of Accounting & Treasury | N/A | N/A | N/A |
Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management | N/A | N/A | N/A |
Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR | Chief Human Resources Officer | N/A | N/A | N/A |
Dr. Anuj Gaggar M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1978 |
Mr. Thomas E. Rollins | Executive Officer | 472.55k | N/A | 1956 |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases in the United States. It develops ABI-5366 and ABI-1179, which is in Phase 1a/1b clinical trial to treat recurrent genital herpes; and ABI-6250, an oral hepatitis delta virus entry inhibitor that is in Phase 1a clinical studies. The company also offers ABI-4334, a next-generation capsid assembly modulator which is in Phase 1b clinical trials, for the treatment of hepatitis B virus. In addition, it provides an oral non-nucleoside polymerase inhibitor indicated to treat transplant-associated herpesviruses; and small molecule interferon-a receptor to treat hepatitis B and delta virus. Assembly Biosciences, Inc. has a collaboration agreement with Gilead Sciences, Inc. that licenses its HPI program and its NNPI program. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Assembly Biosciences, Inc.’s ISS governance QualityScore as of 1 May 2024 is 3. The pillar scores are Audit: 2; Board: 4; Shareholder rights: 2; Compensation: 6.